AURA Phase 2 readout: a positive outcome, +7.9%

On March 31, 2026, AU-011 — Aura Biosciences, Inc. (Eye Cancer) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +7.9% in the window around the event. It had already run +6.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.